Posted inMarket BTIG Raises Climb Bio Stock Price Target to $32 Following Phase 1 Data BTIG has increased its price target for Climb Bio stock to $32 following promising phase 1 clinical trial data results. Posted by Prasenjit Bhowmik September 16, 2026
